Aurobindo Pharma’s subsidiary Theranym Biologics is investing up to $175 million to build a new large-scale biologics manufacturing facility, strengthening its contract manufacturing partnership with MSD and expanding its presence in high value biologics.
Glimpse:
Announced in April 2026, Theranym Biologics will invest between $150 million and $175 million to establish a greenfield drug substance manufacturing facility (Unit 2). The plant will feature large scale mammalian cell culture bioreactors with around 60,000-litre capacity and advanced purification systems. The facility will manufacture biologics for both domestic and global markets under its partnership with MSD (Merck Sharp & Dohme).
Aurobindo Pharma’s biologics arm, Theranym Biologics, has announced a major investment plan of up to $175 million to set up a new biologics manufacturing facility, marking a significant step in the company’s strategic shift toward high-value biologics.
The new facility, referred to as Unit 2, will be developed as a greenfield project and equipped with advanced mammalian cell culture bioreactors with a total capacity of approximately 60,000 litres. It will also include sophisticated downstream purification infrastructure required for producing complex biologic drug substances.
This expansion is part of an extended agreement with MSD (Merck Sharp & Dohme Singapore), under which Theranym will manufacture and supply biologic drug substances. The collaboration builds on an earlier contract manufacturing agreement signed in 2024 and further strengthens Aurobindo Pharma’s position in the global biologics CDMO (contract development and manufacturing organization) space.
The facility is expected to cater to both domestic and international markets, addressing the growing global demand for biologics, which are more complex and higher margin therapies compared to traditional generic drugs.
This move reflects Aurobindo Pharma’s broader strategy to diversify beyond its traditional generics business and enter the fast growing biologics segment, which offers better pricing power, longer product life cycles, and higher barriers to entry.
However, the investment also comes with challenges, including high capital requirements, long gestation periods, and execution risks associated with large-scale biologics manufacturing. Success will depend on timely project execution, regulatory approvals, and sustained demand from global partners like MSD.
“This expansion strengthens Aurobindo’s biologics manufacturing footprint.”
By
HB Team
Related News
